291 related articles for article (PubMed ID: 24892807)
61. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
62. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
[TBL] [Abstract][Full Text] [Related]
63. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
[No Abstract] [Full Text] [Related]
64. CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells.
Hu HM; Winter H; Ma J; Croft M; Urba WJ; Fox BA
J Immunol; 2002 Nov; 169(9):4897-904. PubMed ID: 12391201
[TBL] [Abstract][Full Text] [Related]
65. Single-cell data revealed exhaustion of characteristic NK cell subpopulations and T cell subpopulations in hepatocellular carcinoma.
Cui Z; Li H; Liu C; Wang J; Chen C; Hu S; Zhao X; Li G
Aging (Albany NY); 2024 Apr; 16(7):6550-6565. PubMed ID: 38604154
[TBL] [Abstract][Full Text] [Related]
66. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
Bertrand F; Rochotte J; Colacios C; Montfort A; Tilkin-Mariamé AF; Touriol C; Rochaix P; Lajoie-Mazenc I; Andrieu-Abadie N; Levade T; Benoist H; Ségui B
Cancer Res; 2015 Jul; 75(13):2619-28. PubMed ID: 25977337
[TBL] [Abstract][Full Text] [Related]
67. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity.
Prins RM; Incardona F; Lau R; Lee P; Claus S; Zhang W; Black KL; Wheeler CJ
J Immunol; 2004 Feb; 172(3):1602-11. PubMed ID: 14734741
[TBL] [Abstract][Full Text] [Related]
68. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
69. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
70. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.
Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F
Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136
[TBL] [Abstract][Full Text] [Related]
71. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
72. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
73. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
Zhang Q; Hossain DM; Nechaev S; Kozlowska A; Zhang W; Liu Y; Kowolik CM; Swiderski P; Rossi JJ; Forman S; Pal S; Bhatia R; Raubitschek A; Yu H; Kortylewski M
Blood; 2013 Feb; 121(8):1304-15. PubMed ID: 23287859
[TBL] [Abstract][Full Text] [Related]
74. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
75. Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma.
Labala S; Jose A; Venuganti VV
Colloids Surf B Biointerfaces; 2016 Oct; 146():188-97. PubMed ID: 27318964
[TBL] [Abstract][Full Text] [Related]
76. Self-reactive T cell receptor-reactive CD8+ T cells inhibit T cell lymphoma growth in vivo.
Gonthier M; Llobera R; Arnaud J; Rubin B
J Immunol; 2004 Dec; 173(11):7062-9. PubMed ID: 15557204
[TBL] [Abstract][Full Text] [Related]
77. Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals.
Yun HM; Oh JH; Shim JH; Ban JO; Park KR; Kim JH; Lee DH; Kang JW; Park YH; Yu D; Kim Y; Han SB; Yoon DY; Hong JT
Cell Death Dis; 2013 May; 4(5):e640. PubMed ID: 23703385
[TBL] [Abstract][Full Text] [Related]
78. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells.
Yuan CH; Sun XM; Zhu CL; Liu SP; Wu L; Chen H; Feng MH; Wu K; Wang FB
Oncotarget; 2015 Oct; 6(31):32138-53. PubMed ID: 26451607
[TBL] [Abstract][Full Text] [Related]
79. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
80. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.
Wang CW; Chung WH; Cheng YF; Ying NW; Peck K; Chen YT; Hung SI
J Allergy Clin Immunol; 2013 Sep; 132(3):713-722.e11. PubMed ID: 23791505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
